Liver Transplantation With Tregs at MGH

Phase 1/2 Active not recruiting 9 enrolled National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.

Timeline

Start: 2019-03-29
Primary completion: 2026-02-06
Completion: 2027-04-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	arTreg-CSB	Unknown	2.5e+06 cells	Intravenous
Subject	arTreg-CSB	Unknown	1.25e+08 cells	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	40 mg/kg	Intravenous
Background	Everolimus	Small molecule	1.5 mg	Oral

Indications

No indication recorded.